Differing Outcome of Experimental Autoimmune Encephalitis in Macrophage/Neutrophil- and T Cell-Specific gp130-Deficient Mice

Kristian Holz¹, Marco Prinz², Stefanie M. Brendecke², Alexandra Hölscher¹, Fengyuan Deng¹, Hans-Willi Mitrücker⁴, Stefan Rose-John⁵,⁶ and Christoph Hölscher¹,⁶,⁷*

¹ Division of Infection Immunology, Research Center Borstel, Borstel, Germany, ² Institute of Neuropathology, Medical Faculty University of Freiburg, Freiburg, Germany, ³ BIOSS Center for Biological Signaling Studies, University of Freiburg, Freiburg, Germany, ⁴ Institute of Immunology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁵ Department of Biochemistry, Christian-Albrechts-University, Kiel, Germany, ⁶ Cluster of Excellence Inflammation-at-Interfaces, Borstel-Kiel-Lübeck-Plön, Germany, ⁷ Priority Area Infection, Research Center Borstel, Borstel, Germany

gp130 cytokines are differentially involved in regulating the T helper (H) 17-driven pathogenesis of experimental autoimmune encephalomyelitis (EAE), the animal model of human multiple sclerosis. Interleukin (IL)-6 directly promotes the development of TH17 cells through the gp130/IL-6R complex. By contrast, IL-27 has been shown to suppress a TH17 immune response by gp130/IL-27R-alpha (α) receptor ligation. The IL-27-dependent regulation of a TH17 development could be mediated on the level of CD4 T cells. However, because IL-27 also suppresses the secretion of the TH17-driving cytokines IL-6 and IL-12/23p40 in accessory cells, TH17 immune responses may also be controlled by IL-27 on the level of macrophages and/or neutrophils. To analyze these opposing effects of gp130 engagement on the pathogenesis of EAE, we immunized CD4⁺ T cell-specific gp130-deficient (CD4cre⁺gp130loxP/loxP) and macrophage/neutrophil-specific gp130-deficient (LysMcre⁺gp130loxP/loxP) mice with the myelin-oligodendrocyte-glycoprotein peptide MOG35–55. Whereas inflammatory immune responses, TH17 differentiation, and pathology in CD4cre⁺gp130loxP/loxP mice were mitigated, disease progression was eventually enhanced in LysMcre⁺gp130loxP/loxP mice. Exacerbated disease in MOG35–55-immunized LysMcre⁺gp130loxP/loxP mice was associated with an elevated development of TH17 cells and increased infiltration of the central nervous system with leukocytes indicating a suppressive role of macrophage/neutrophil-gp130. To further prove IL-6 to be responsible for the control of inflammation during EAE through gp130 on macrophages/neutrophils, we immunized LysMcre⁺IL-6RloxP/loxP mice. In contrast to LysMcre⁺gp130loxP/loxP mice, neuropathology in MOG35–55-immunized macrophage/neutrophil-specific IL-6R-deficient mice was not enhanced indicating that the alleviation of EAE through macrophage/neutrophil-gp130 is mediated independently of IL-6. Together, this different pathology in macrophage/neutrophil- and CD4 T cell-specific gp130-deficient mice suggests that gp130 cytokines modulate TH17 inflammation differentially by targeting distinct cell types.

Keywords: experimental autoimmune encephalomyelitis/multiple sclerosis, gp130 cytokine, interleukin-6, interleukin-27, inflammation mediators
INTRODUCTION

Multiple sclerosis (MS) is one of the most common neurological diseases worldwide. It is well documented that MS represents an inflammatory demyelinating disease of the central nervous system (CNS) which is mediated by pathogenic CD4+ T helper (H) cells (1). Using the animal model for MS known as experimental autoimmune encephalomyelitis (EAE), recent studies could show that autoreactive myelin-specific TH17 cells are responsible for the induction and maintenance of neuroinflammation whereas regulatory T cells (Tregs) represent the most relevant cell line with respect to EAE resistance (2). Originally named for their ability to produce interleukin (IL)-17A and IL-17F, TH17 cells are crucial for the amplification of neuroinflammation by activating epithelial cells and attracting other immune cells because of their ability to express additional pro-inflammatory mediators such as tumor necrosis factor (TNF), granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, IL-21, or IL-22 (3, 4). Since the discovery of TH17 cells, numerous studies have focused on attenuating the impact of pathogenic TH17 cells as a therapeutic strategy (5–7).

In the EAE model, the initial differentiation of autoreactive myelin-specific TH17 cells is induced in lymphoid organs via immunization with an emulsion of the complete Freund’s adjuvant (CFA) and the myelin-oligodendrocyte-glycoprotein peptide (MOG)35–55. Comparative analyses of gene-deficient mice showed that especially the pro-inflammatory cytokine IL-6 together with TGFβ is considered the most important pro-inflammatory mediator for the development of TH17 cells (8). This has convincingly been shown by using IL-6-deficient (−/−) mice, which are completely resistant to EAE (9–11). By contrast, in the absence of IL-6 secretion, the sole presence of TGFβ leads to the development of Th0 (12–16). Therefore, IL-6 that uses the gp130/IL-6R receptor complex for signaling constitutes a key role because it first suppresses the development of Th0 and on the other hand directly induces the development of pathogenic TH17 cells (12, 17).

In addition to the gp130 cytokine IL-6, the heterodimeric cytokine IL-27 also uses the receptor subunit gp130 for signaling (18). However, binding to the gp130/IL-27R-alpha (α) receptor complex IL-27 mediates inhibitory effects on the development of pathogenic TH17 cells and therefore acts contrary to the pro-inflammatory cytokine IL-6 (19–21). In addition, antagonizing gp130 signaling by overexpression of IL-27p28 in vivo also ameliorated EAE pathogenesis and reduced tissue infiltration due to decreased lineage stability of effector T cells (22, 23). Thus, IL-27 plays a crucial role in protection against EAE development. In fact, the induction of EAE in IL-27Rα−/− mice led to an significant increase in neuropathology which was accompanied by an enhanced expression of pro-inflammatory cytokines (24, 25). Hence, in the EAE model the gp130 cytokines IL-6 and IL-27 exert diametrically opposed effects on the development of TH17 cells.

Whereas gp130 is ubiquitously expressed, the cell type-specific effects of IL-6 and IL-27 signaling relies on the expression of the private cytokine-specific receptor subunits IL-6R and IL-27Rα, respectively. In addition to CD4+ T cells, activated macrophages and neutrophils are also capable of expressing IL-6R and IL-27Rα together with gp130 (26–32). However, not much is known about the effect of gp130 cytokines on these cells. Macrophage/neutrophil-gp130 has been shown to modulate the dynamics of innate immune cell recruitment and activation in the acute stages of intestinal inflammation (30). On the other hand, it has been repeatedly documented that IL-6 as well as IL-27 suppress inflammatory immune responses of macrophages (26–29, 31, 32). In addition, IL-27 also regulates neutrophil development and function (33–35). Thus, IL-6 and IL-27 exhibit essential regulatory functions and consequently indirectly modulate inflammatory immune responses. Therefore, gp130 cytokines also may indirectly regulate adaptive immune responses during the course of EAE by modulating the secretion of inflammatory mediators by macrophages.

To elucidate the differential function of T cell-gp130 and macrophage/neutrophil-gp130 on the development of EAE, conditional gp130+/−/+loxP mice were crossed with T cell-specific CD4creloxP and macrophages/neutrophil-specific lysozyme (Lys) McreloxP deleter mice. After immunization with MOG35-55/CFA, the development of EAE in CD4cre+loxP/loxP and LysMcre+loxP/loxP mice was analyzed in comparison with the respective cre-negative littermates. To further analyze macrophage/neutrophil-specific effects on neuropathology mediated by IL-6, we also included immunized LysMcre+IL-6RloxP/loxP mice.

RESULTS

MOG35-55-Immunized CD4cre+loxP/loxP Mice Are Resistant to EAE Induction

gp130 cytokines like IL-6 and IL-27 induce different mechanisms in various cell types. Whereas IL-6 promotes the differentiation of CD4+ T cells to TH17 cells, IL-27 suppresses TH17 development of CD4+ T cells. Accordingly, both cytokines differentially modulate the development of CD4+ T cells to pathogenic TH17 cells during the course of EAE. To elucidate the function of gp130-dependent cytokines on activated T cells, conditional gp130+/−/+loxP mice were crossed with T cell-specific CD4creloxP deleter mice. Examination of the efficient deletion of gp130 in CD4+ T cells was performed by flow cytometry of single cell suspension of spleens isolated from CD4creloxP and CD4creloxP/loxP mice. Whereas gp130 was found to be readily expressed on CD4+ T cells of CD4creloxP mice, it was nearly absent on CD4+ T cells of CD4creloxP/loxP mice (Figure S1 in Supplementary Material). To analyze the impact of gp130 signaling on T cells for the development of EAE, CD4creloxP/loxP littermates were immunized with MOG35-55 emulsified in CFA and monitored for EAE symptoms. Upon immunization, all CD4creloxP/loxP littermates developed neurologic symptoms such as tail weakness and paralysis, starting 2 weeks after EAE induction (mean maximal score: 3.04 ± 0.64) (Figure 1A). By contrast, CD4creloxP/loxP littermates showed significantly reduced clinical signs and were almost resistant to the induction of EAE (mean maximal score: 0.42 ± 1.02). To assess demyelination and axonal damage within the CNS of diseased mice, histological analyses of...
FIGURE 1 | Continued
spinal cord sections were carried out 21 days after immunization (Figure 1B). The extent of demyelination and the loss of axons were detected by luxol fast blue (LFB) staining and by staining of amyloid precursor protein (APP) deposits. Upon quantification, immunized CD4cre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> mice showed significantly less regions of demyelination as well as fewer APP<sup>+</sup> deposits compared with cre-negative littermates (Figure 1C). Infiltration of the CNS with leukocytes is key to the pathology of EAE. We therefore performed immunohistochemical staining of CD3<sup>+</sup> T cells, MAC3<sup>+</sup> macrophages, and B220<sup>+</sup> B cells (Figure 1B). Quantification of the accumulation of these cells revealed that the infiltration in CD4cre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> mice was significantly reduced 15 days after immunization (day 15) was significantly reduced in CD4cre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> mice (Figure 1C). Thus, this distinct neuropathology observed in histological analyses of immunized CD4cre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> and CD4cre<sup>+</sup>gp130<sup>loxP/loxP</sup> mice reflected the development of clinical EAE symptoms after immunization.

**Immunized CD4cre<sup>+</sup>gp130<sup>loxP/loxP</sup> Mice Show Significantly Reduced TH17 and TH1 Development**

To analyze the instructive events that account for EAE-susceptibility of immunized CD4cre<sup>+</sup>gp130<sup>loxP/loxP</sup> mice and CD4cre<sup>+</sup>gp130<sup>loxP/loxP</sup> littermates in more detail, the frequency of TH1 and TH17 cells was determined at different time points early after immunization (Figures 2A,B). Both, in lymph nodes as well as within the CNS, intracellular staining of IL-17A and IFNγ in activated CD4<sup>+</sup> T cells showed that the development of inflammatory TH17 and TH1 cells was significantly reduced in immunized CD4cre<sup>+</sup>gp130<sup>loxP/loxP</sup> mice (Figures 2A,B). More precisely, after restimulation of single cell suspensions with anti-CD3/CD28, the frequency of TH17 cells was dramatically reduced in lymph nodes and spleen of immunized CD4cre<sup>+</sup>gp130<sup>loxP/loxP</sup> mice (Figure 2A left). The frequency of TH1 cells was significantly reduced 15 days after immunization (Figure 2A right). Determining the percentage of TH17 and TH1 cells referring to all CNS-infiltrated CD4<sup>+</sup> cells revealed that the initial infiltration of TH1 cells (day 8) and TH17 cells (day 15) was significantly reduced in CD4cre<sup>+</sup>gp130<sup>loxP/loxP</sup> mice compared with cre-negative littermates (Figure 2B).

Collectively, these data indicate that the resistance observed in immunized CD4cre<sup>+</sup>gp130<sup>loxP/loxP</sup> mice resulted from reduced neuropathology due to diminished TH17 and TH1 cell development as well as ameliorated CNS-infiltration already at an early stage of the disease. Accordingly, the deletion of gp130 on T cells prevented the development of inflammatory T cells, meaning that the expression of T cell-gp130 is essential for TH17 and TH1 cell development.

**LysMcre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> but Not LysMcre<sup>−/−</sup>IL-6R<sup>loxP/loxP</sup> Mice Show Significantly Increased Disease Progression After MOG<sub>35–55</sub>-Immunization During the Chronic Stage of the Disease**

gp130 cytokines like IL-6 and IL-27 not only exert distinct functions on activated T cells but they also serve as inhibitors for activated macrophages/neutrophils in a gp130-dependent manner. Therefore, the effect of gp130 cytokines on the development of EAE may also be regulated indirectly by suppressing the TH17-driving cytokine secretion of activated macrophages/neutrophils. To analyze the function of gp130 on macrophages/neutrophils during the course of EAE, conditional gp130<sup>loxP/loxP</sup> mice were crossed with macrophage/neutrophil-specific LysMcre<sup>+</sup> deleter mice. Cre-positive offspring of this breeding was shown to efficiently delete gp130 on macrophages (31). Immunization of LysMcre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> mice and LysMcre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> littermates with MOG<sub>35–55</sub>/CFA demonstrated that the deletion of gp130 on macrophages/neutrophils of LysMcre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> mice resulted in significantly increased susceptibility to EAE (Figure 3A). More precisely, whereas the onset was similar in both mouse strains, the chronic effector phase of the disease was changed, with an enhanced mean maximal score in LysMcre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> mice (3.05 ± 0.37 versus 2.68 ± 0.46 in LysMcre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> littermates). Because oxidative stress appears to be a key mechanism promoting CNS tissue damage in EAE and expression of the gp91phox subunit of the NADPH oxidase complex correlates with the degree of EAE (36), we quantified gene expression of gp91phox in the CNS of immunized mice and found that 15 days after immunization the expression of gp91phox was not significantly increased in LysMcre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> mice (Figure 3B). Using LFB staining of spinal cord sections isolated 21 days after immunization, we could not detect a significantly different demyelination of the white matter in LysMcre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> mice compared with cre-negative littermates (Figures 3C,D). In addition, by determining the amount of APP<sup>+</sup> deposits, we also found no significantly increased axonal damage in these mice at this early time point. Immunohistochemical staining and subsequent quantification of infiltrating CD3<sup>+</sup> T cells, MAC3<sup>+</sup> macrophages and B220<sup>+</sup> B cells did not also reveal an overall significantly increased inflammation in LysMcre<sup>−/−</sup>gp130<sup>loxP/loxP</sup> mice (Figures 3C,D).

Because IL-6 and IL-27 both suppress inflammatory immune responses of macrophages (26–29, 31, 32), we were wondering whether either cytokine is responsible for the increased pathology in the absence of macrophage/neutrophil-gp130. To analyze the specific effect of IL-6 on macrophages during
Figure 2: Continued

A. TH17 and TH1 responses in gp130-deficient mice.

- CD4cre\textsuperscript{neg} gp130\textsuperscript{loxP/loxP}: 4.71% IL-17A, 3.36% IFN-γ
- CD4cre\textsuperscript{pos} gp130\textsuperscript{loxP/loxP}: 0.51% IL-17A, 0.61% IFN-γ

B. Lymph node IL-17A and IFN-γ responses.

- PBS/C3D28: 34.35% IL-17A, 24.19% IFN-γ
- CD3/C3D28: 10.82% IL-17A, 19.07% IFN-γ

CNS responses.

- PBS/C3D28: 30% IL-17A, 20% IFN-γ
- CD3/C3D28: 40% IL-17A, 30% IFN-γ

* p < 0.05, ** p < 0.01
EAE, we immunized LysMcre<sup>pos</sup>IL-6R<sup>loxP/loxP</sup> mice that have been shown to efficiently delete IL-6R on macrophages (37, 38) and LysMcre<sup>pos</sup>IL-6R<sup>loxP/loxP</sup> littermates with MOG<sub>35–55</sub>/CFA. In contrast to a macrophage/neutrophil-specific gp130 deficiency (see Figure 3A), a deletion of IL-6R on macrophages/neutrophils in LysMcre<sup>pos</sup>IL-6R<sup>loxP/loxP</sup> mice did not increase the susceptibility to EAE (Figure 4).

In summary, the immunization of LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice and LysMcre<sup>pos</sup>IL-6R<sup>loxP/loxP</sup> mice with MOG<sub>35–55</sub>/CFA demonstrated that the development of EAE symptoms during the chronic stage of the disease is regulated on the level of activated macrophages/neutrophils.

**Predominant TH17 and TH1 Development in Immunized LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> Mice**

To analyze the impact of macrophage/neutrophil-gp130 on the initial development of pathogenic T cells during the course of EAE, the frequency of TH1 and TH17 cells in lymphoid organs was determined by flow cytometry analyses (Figure 5). Whereas 8 days after immunization, the frequency of TH17 cells was still comparable in both groups, 14 days after immunization LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice show significantly more TH17 cells compared with LysMcre<sup>neg</sup>gp130<sup>loxP/loxP</sup> littermates (3.1 versus 1.4%). Hence, only in LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice the frequency of TH17 cells increased during the course of EAE whereas the frequency of TH17 cells in immunized LysMcre<sup>neg</sup>gp130<sup>loxP/loxP</sup> mice remained unchanged. The development of TH1 cells was not significantly different in immunized LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice compared with LysMcre<sup>neg</sup>gp130<sup>loxP/loxP</sup> littermates. Therefore, these results illustrate that the deletion of gp130 on macrophages/neutrophils amplified the development of inflammatory TH17 cells after EAE induction as early as 14 days after immunization.

**Immunized LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> Mice Show Enhanced CNS-Infiltration**

After immunization with MOG<sub>35–55</sub>/CFA, activated leukocytes gain entry into the CNS via the blood–brain barrier (39–42). To investigate the effect of an initially increased frequency of inflammatory T cells in the periphery on CNS-infiltration, single cell suspensions of CNS-infiltrated cells were analyzed by flow cytometry analyses (Figure 6). The influx of CD45<sup>+</sup> leukocytes (Figure 6A), CD4<sup>+</sup> T cells (Figure 6B), F4/80<sup>+</sup>MHC-II<sup>+</sup> macrophages (Figure 6C), and CD11c<sup>+</sup>MHC-II<sup>+</sup> dendritic cells (Figure 6D) was examined 8 and 14 days after EAE induction, respectively. Fourteen days after immunization, the frequency of CD45<sup>+</sup> leukocytes was significantly increased in immunized LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice compared with cre-negative littermates (Figure 6). The frequency of CD4<sup>+</sup>CD44<sup>+</sup>CD90.2<sup>+</sup>T cells was not statistically different in these mice as well. Whereas the proportion of F4/80<sup>+</sup>MHC-II<sup>+</sup> macrophages was also not statistically increased, the frequency of CD11c<sup>+</sup>MHC-II<sup>+</sup> dendritic cells in all viable CD4<sup>+</sup> cells was clearly enhanced in immunized LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice. Together, the enhanced inflammatory immune response in peripheral organs of immunized LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice led to an increased infiltration of CD45<sup>+</sup> leukocytes and CD11c<sup>+</sup>MHC-II<sup>+</sup> dendritic cells into the CNS already 14 days after immunization.

**Expression of TH17-Driving Cytokines and Pro-Inflammatory Mediators Within the CNS of Immunized LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> Mice**

To assess the immune response within the CNS of immunized LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> and LysMcre<sup>neg</sup>gp130<sup>loxP/loxP</sup> mice at the onset of disease, gene expression studies were performed. At different time points after EAE induction, CNS homogenates were assayed for gene expression of Il16, Il12b, Ifng, Il17a, and Tnf by quantitative real-time RT-PCR (Figure 8). Fifteen days after immunization, LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice showed no statistically higher expression of the TH17-driving cytokine IL-6 as LysMcre<sup>neg</sup>gp130<sup>loxP/loxP</sup> littermates. The Il12b-expression was comparable in both groups.

Furthermore, as marker for an inflammatory immune reaction, we also monitored the expression of Il17a, Ifng, and Tnf. Seven as well as 15 days after immunization LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice showed no significantly enhanced expression of IL-17A compared with LysMcre<sup>neg</sup>gp130<sup>loxP/loxP</sup> littermates. In addition, 15 days after immunization gene expression of the pro-inflammatory cytokines, Ifng and Tnf were also not significantly
FIGURE 3 | Continued
increased, respectively. Together, early after immunization, the inflammatory immune response in the CNS was not significantly elevated in LysMcre<sup>pos</sup> gp130<sup>loxP/loxP</sup> mice.

**DISCUSSION**

gp130 cytokines, which are mainly expressed by antigen-presenting cells upon activation, differentially modulate the development of inflammatory immune responses *in vivo*. Within the gp130 cytokine family the monomeric cytokine IL-6 as well as the heterodimeric cytokine IL-27, composed of p28 and EBI-3, represent the most relevant members during T cell activation. Based on *in vitro* studies, pro-inflammatory properties of IL-6 as well as anti-inflammatory effects of IL-27 during TH17 cell differentiation are attributed to a differential signal transduction in naive T cells. Recently, it has been shown that the ability to access signal transducers and activators of transcription (STAT) 1 is responsible for the opposing effects of IL-6 and IL-27 on T cells (43). The importance of gp130 cytokines in EAE pathogenesis has persuasively been shown utilizing mice with systemic deletions of IL-6, IL-27R<sub>α</sub>, and EBI-3, respectively (9–11, 19, 24, 44). In addition to T cells, activated macrophages also express gp130 together with the cytokine-specific receptor subunit IL-6R and IL-27R<sub>α</sub> (26–29, 31, 32). However, the autocrine effect of gp130 signal transduction in activated macrophages is poorly investigated, although these cells play key roles in controlling the development of T cells through antigen presentation, expression of co-stimulatory receptors, and via the secretion of inflammatory mediators. Thus, the analysis of cell type-specific effects mediated by gp130 cytokines is essential to prevent negative side effects of immunotherapy targeting IL-6- or IL-27-signaling pathways.
In this study, immunized T-cell-specific gp130-deficient mice were devoid of CNS-infiltration due to reduced frequencies of TH17 and TH1 cells in peripheral organs. Therefore, on the level of T cells, gp130 expression mediates CNS-infiltration and causatively induces EAE by particularly promoting the early development of pathogenic TH17 cells, and the outcome of EAE in T-cell-specific gp130-deficient mice reflects the course of EAE in systemic IL-6-deficient mice (9–11). IL-6 could either directly promote the development of autoreactive TH17 cells (45–47) or indirectly by suppressing the effect of Treg (12, 48). Hence, in our study, the TH17-polarizing effect of IL-6 could be attributed to both, the direct effect of IL-6 through T cell-gp130 and to the suppressive effect of IL-6 on Treg.

As gp130 cytokines, IL-6 and IL-27, have divergent effects on TH17 differentiation. In contrast to IL-6, IL-27 directly inhibits the development and effector response of TH17 cells (19, 21, 49). With respect to this putative T-cell-gp130-mediated anti-inflammatory effect through IL-27, however, we cannot conclude from our data that IL-27 directly suppresses TH17 cells in EAE because the absence of IL-6-mediated signaling in CD4cre^{neg}gp130^{loxP/loxP} mice impedes TH17 development. In summary, using T-cell-specific gp130-deficient mice our data point to the T-cell-specific impact of IL-6 through gp130 on the development of autoreactive TH17 cells and the pathogenesis of EAE.

In addition to T cells, activated macrophages and neutrophils likewise express functional receptor complexes for IL-6 as well as IL-27. Therefore, IL-6 and IL-27 indirectly influence T cell immune responses by regulating the effector function of activated macrophages and neutrophils. In contrast to T cells, it has convincingly been shown that IL-6- and IL-27-dependent signal transduction in macrophages lead to inhibition and to reduced secretion of inflammatory cytokines (26–29, 31, 32). Moreover, upon activation, myeloid cells play a crucial role in the development of tissue inflammation and autoimmunity (50–52). Initial experiments suggest that macrophage-gp130 modulates TH17 cell development by downregulating the secretion of...
Figure 6 | Characterization of infiltrates in immunized LysMcre<sup>neg</sup>gp130<sup>loxP/loxP</sup> mice and LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice. LysMcre<sup>neg</sup>gp130<sup>loxP/loxP</sup> mice (white bars) and LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> littermates (black bars) were immunized with MOG<sub>35–55</sub>/CFA. During the course of EAE, the frequency of (A) CD45<sup>+</sup> lymphocytes, (B) activated CD44<sup>+</sup> CD4<sup>+</sup> T cells, (C) F4/80<sup>+</sup>MHC-II<sup>+</sup> macrophages, and (D) CD11c<sup>+</sup>MHC-II<sup>+</sup> dendritic cells was determined by flow cytometry. For the analysis, single cell suspensions of CNS-infiltrating lymphocytes were performed at different time points. Representative flow cytometry density plots of cells isolated on day 14 are shown. Data represent means and SEs of five mice per group. Statistical analysis was performed using Mann–Whitney test. Asterisks indicate statistical significance (*p ≤ 0.05).
inflammatory mediators (31). A recent study revealed that the development of autoreactive T cells and subsequent EAE pathogenesis is controlled by the IL-27-mediated suppression of dendritic cell functions (53). Using the nephrotic nephritis model of acute crescentic glomerulonephritis recent studies could show that IL-6-mediated dampening of macrophage activation protects tissues from overshooting immune responses (38). The gp130 cytokines IL-6 and IL-27 may also modulate inflammation through gp130 on neutrophils. The effect of IL-6 on neutrophils, however, appears to be pro- and anti-inflammatory (54–56). By contrast, IL-27 has been described to clearly suppress neutrophil development and function (33–35). Cre-recombinase activity controlled by the lysozyme M promoter leads to deletion of loxP-flanked gene sequences in both macrophages and neutrophils (57). Because inflammatory macrophages (58–60) as well as inflammatory neutrophils (61–63) promote disease progression in EAE, both cell types may, when uncontrolled, contribute to the increased pathology in LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice shown in this study. However, since distinct subpopulations of macrophages and neutrophils (i.e., alternatively activated macrophages and myeloid-derived suppressor cells) (64–66) rather act anti-inflammatory or suppressive during EAE, the lack of macrophage/neutrophil-gp130 may also hinder the activation and development of these protective cells.

Our present study suggests that gp130 cytokines suppress EAE pathogenesis on the level of macrophages and/or neutrophils. A closer examination of the kinetic effects in the periphery and the CNS of immunized LysMcre<sup>pos</sup>gp130<sup>loxP/loxP</sup> mice indicates that the macrophage/neutrophils-gp130-mediated effect on TH17 development in the draining lymph node and the leukocyte infiltration in the CNS proceeds at a rather late time point when first EAE symptoms already appear. This delayed increase in inflammation indicates that gp130 on macrophages/neutrophils does not suppress the initial development of TH17 cells and inflammation. It
rather limits the accumulation of TH17 cells and leukocytes in the periphery and the CNS at the onset of the chronic disease, respectively. At this time point, the inflammation in the CNS and the disease was not significantly different in LysMcre\textsuperscript{moxgp130\textsuperscript{lizP/lizP}} mice and cre-negative littermates. However, the disease began to worsen and secondary to the increased accumulation of TH17 cells, and leukocytes symptoms were significantly elevated in the absence of macrophage/neutrophil-gp130 when the clinical score was decreasing in gp130-competent mice. Hence, gp130 signaling in macrophages/neutrophils appears to maintain CNS inflammation indirectly through the eventual accrual of TH17 cells and leukocytes and/or directly by modulating the effector response in macrophages/neutrophils.

Nonetheless, because macrophage/neutrophil-specific gp130-deficient mice develop an aggravated course of EAE compared with control littermates but not macrophage/neutrophil-specific IL-6R-deficient mice this regulatory effect on macrophages is mediated by gp130 cytokines independently of IL-6. In line with our observation, IL-6 has recently been shown to promote the development of pathogenic TH17 cells in EAE by IL-6-transpresentation to T cells through the IL-6R on dendritic cells (67). Overall, gp130 cytokines control pathogenic immune responses not solely via T cell-gp130 but also by regulating activated macrophages/neutrophils.

Recent studies revealed that CNS-dependent gp130 expression on astrocytes and neurons support cell survival and contribute to EAE pathogenesis (68–70) and therefore give evidence that cell type-specific effects of gp130 cytokines differentially contribute to the regulation of autoreactive inflammatory processes. However, additional experiments are needed to clarify which cells

**FIGURE 8** Expression of cytokines during the course of EAE. Immunized LysMcre\textsuperscript{moxgp130\textsuperscript{lizP/lizP}} mice (white bars) show enhanced expression of Il6, Il12b, Ifng, Il17a, and Tnf compared with LysMcre\textsuperscript{neggp130\textsuperscript{lizP/lizP}} litterates (black bars). At different time points after EAE induction, CNS homogenates were assayed for gene expression by quantitative real-time RT-PCR. Data are expressed as ratio of induced factors versus endogenous Hprt and expressed as means and SEs of three mice per group. Statistical analysis was performed using Mann–Whitney test.
in the CNS are responsive to gp130 cytokines. In this context, our experiments demonstrate that gp130 cytokines possess cell type-specific effects on T cells and macrophages/neutrophils. Whereas for example IL-6 preferentially leads to the phosphorylation of STAT3 dimers, IL-27 mainly induces the formation of phosphorylated STAT1-monomers and STAT1/3-dimers (49, 71). On a functional level, the differential consequences of T cell-gp130 and macrophage/neutrophil-gp130 signaling during EAE can therefore be explained by distinct phosphorylation of intracellular STAT proteins and thus the induction of different transcription factors. In addition, a cell type-specific ability to access STAT1 may also be responsible for the differential effect of gp130-mediated signaling in CD4 T cells and macrophages (43).

In addition to IL-6 and IL-27, other cytokines also belong to the gp130 cytokine family including IL-35, IL-11, leukemia inhibitory factor (LIF), oncostatin m, ciliary neurotrophic factor, and cardiotoxin-1 (CT-1) (72–74). Also the IL-27p28 subunit (IL-30) induces STAT3-mediated signals independently of the gp130-mediated signaling in CD4 T cells and macrophages (43).

Whereas for example IL-6 preferentially leads to the phosphorylation of STAT3 dimers and thus the induction of different transcription factors, this anti-inflammatory property of the gp130 cytokine LIF and IL-35 have also been shown to inhibit TH17 immune responses. In addition, a cell type-specific ability to access STAT1 may also be responsible for the differential effect of gp130-mediated signaling in CD4 T cells and macrophages (43).

In addition to IL-6 and IL-27, other cytokines also belong to the gp130 cytokine family including IL-35, IL-11, leukemia inhibitory factor (LIF), oncostatin m, ciliary neurotrophic factor, and cardiotoxin-1 (CT-1) (72–74). Also the IL-27p28 subunit (IL-30) induces STAT3-mediated signals independently of the gp130-mediated signaling in CD4 T cells and macrophages (43).

Whereas for example IL-6 preferentially leads to the phosphorylation of STAT3 dimers and thus the induction of different transcription factors, this anti-inflammatory property of the gp130 cytokine LIF and IL-35 have also been shown to inhibit TH17 immune responses. In addition, a cell type-specific ability to access STAT1 may also be responsible for the differential effect of gp130-mediated signaling in CD4 T cells and macrophages (43).

Whereas for example IL-6 preferentially leads to the phosphorylation of STAT3 dimers and thus the induction of different transcription factors, this anti-inflammatory property of the gp130 cytokine LIF and IL-35 have also been shown to inhibit TH17 immune responses. In addition, a cell type-specific ability to access STAT1 may also be responsible for the differential effect of gp130-mediated signaling in CD4 T cells and macrophages (43).

**MATERIALS AND METHODS**

**Mice**

Breeding pairs of CD4cre<sup>loxp</sup>gp130<sup>loxP/loxP</sup> and LysMcre<sup>loxp</sup>gp130<sup>loxP/loxP</sup> mice (57, 81) were kindly provided by Werner Müller (Braunschweig, Germany) and bred under specific pathogen-free conditions at the Research Center Borstel. IL-6R<sup>loxP/loxP</sup> mice were generated as previously described (82), and LysMcre<sup>loxP</sup>IL-6R<sup>loxP/loxP</sup> mice were raised at the animal facility of the University Medical Center Hamburg-Eppendorf. Experimental mice were between 8 and 12 weeks old. In any given experiment, mice were matched for age, sex, and genetic background. All experiments performed were in accordance with German Animal Protection Law and were approved by the Animal Research Ethics Board of the Ministry of the Environment, Kiel, Germany.

**Induction and Assessment of EAE**

Mice were injected subcutaneously with 100 µg of MOG<sub>35-55</sub> peptide (MEVGWYRSPFSRVVHLYRNGK) emulsified in CFA supplemented with 2 mg/ml killed Mycobacterium tuberculosis H37Ra and injected twice intravenously with 300 ng of pertussis toxin (both Hooke Laboratories). Clinical assessment of EAE was performed daily after disease induction according to the following criteria: 0, no disease; 1, decreased tail tone; 2, hindlimb weakness or partial paralysis; 3, complete hindlimb paralysis; 3, 5, forelimb and hindlimb paralysis; 4, moribund state.

**Preparation of Single Cell Suspensions**

Single cell suspensions of CNS-infiltrates, lymph nodes, and spleen were prepared at different time points. Mice were sacrificed with CO<sub>2</sub> and subsequently perfused with cold PBS. Brain tissue and spinal cord were treated with collagenase A (1 mg/ml, Roche) and DNase I (30 µg/ml, Sigma) for 30 min at 37°C, disrupted by passage through a nylon cell strainer and subsequently isolated by density gradient centrifugation (Percoll, GE Healthcare). Lymph nodes and spleens were strained through 70 µm pore size nylon cell strainer. Recovered vital cells were counted using an automatic cell counter (ViCell<sup>®</sup>; Beckman Coulter), diluted in complete Iscove’s-modified Dulbecco’s medium (IMDM; Gibco) supplemented with 10% FCS (Gibco), 0.05 mM β-mercaptoethanol (Sigma), and penicillin and streptomycin (100 U/ml and 100 µg/ml; Gibco) and used for further experiments.

**Flow Cytometric Analyses**

Cells were stained with primary antibodies to CD45 (BD Biosciences), CD4 (BD Biosciences), CD90.2 (BioLegend), CD44 (BioLegend), F4/80 (BioLegend), MHC-II (eBioscience), and...
CD11c (BioLegend) for 45 min at 4°C. Non-specific antibody binding was blocked by incubation with a cocktail containing anti-FcγRIII/II mAb (clone 2.4G2), mouse, and rat sera.

**Intracellular Cytokine Staining**

For detection of intracellular IFNγ and IL17A cells were incubated with IMDM or stimulated with plate-bound anti-CD3/CD28 mAb (clone 2C11 and clone 37/51 at 10 μg/ml, respectively) for 4 h in the presence of GolgiPlug™ (BD Biosciences). After surface staining with antibodies to CD4, CD90.2, and CD44, cells were fixed and permeabilized with Cytofix/Cytoperm™ (BD Biosciences), and intracellularly accumulated IFNγ and IL-17A were stained. Activated lymphocytes were gated by CD4+CD90.2+ and CD44+ profile. Viable cells were identified by 7-AAD staining. Fluorescence intensity was analyzed using a FACSCanto II (BD Biosciences). Data were acquired with FACSDiva software (BD Biosciences).

**Histology**

Histology was performed as described recently (83). Spinal cords were removed and fixed in 4% formalin-PBS. Subsequently, spinal cords were dissected, embedded in paraffin and sectioned (2–3 μm) before staining with Luxol fast blue (LFB-PAS) to assess the degree of demyelination. For the immunohistochemical detection of macrophages/microglia, T cells, B cells, and axonal damage tissue sections were deparaffinized and pressure cooked in 10 mM citrate buffer, pH 6.0. After peroxidase quenching with 3% H2O2/PBS and blocking with 10% FCS, sections were incubated with primary antibodies against MAC-3 (1:200, BD Bioscience) for macrophages and microglia, CD3 (1:100, MCA1477 Serotec, Düsseldorf, Germany) for T cells, B220 (1:200, BD Bioscience) for B cells, and APP (1:3,000, MAB348, Millipore) for indication of axonal damage overnight followed by the incubation with HRP-conjugated secondary antibodies. Development was performed by using DAB-buffer tablets (Merck, Darmstadt, Germany). Spinal cord sections were evaluated using cell-P software (Olympus).

**Quantitative Real-Time RT-PCR**

Total RNA was extracted by acid phenol extraction. cDNA was obtained using murine Moloney leukemia virus reverse transcriptase (Superscript II, Invitrogen) and oligo-dT (12–18mer; Sigma) as a primer. The following primer sets were used: Hprt: sense 5′-TCC TTC TCA GAC CGC TTT T-3′, antisense 5′-GTT GTC TCA TCA CCA CAA-3′; Il6: sense 5′-GTC ACC AAA CTG GAT ATA ATC AGG A-3′, antisense 5′-CCA GGT AGC TAT GGT GCT CCA GAA-3′, probe 5′-GCC TGC TTG TGG-3′; Il12b: sense 5′-ATG GGT ACC TGT GTC GGT TCC C-3′, antisense 5′-GGA GTC CAG TCC ACC TCT ACA-3′, probe 5′-AGC TGG AGG-3′; Ifng: sense 5′-ATG TGG AGG AAC TGG CAA AA-3′, antisense 5′-TTC AGC ACT TCA AAG AGT CTG AGG TA-3′, probe 5′-CAG-AGC CA-3′; Il17a: sense 5′-TGT GAA GGT CAA CCT CAA AGT CT-3′, antisense 5′-GAG GGA TAT CTA TCA GGT TCG TCA T-3′, probe 5′-GCT CCA GA-3′; Gpx1: sense 5′-TGC CAC CAG TCT GAA ACT CA-3′, antisense 5′-GCA TGG TCT GCA GAA-3′, probe 5′-ACC TGC TG-3′; Tnf: sense 5′-TCT TCT CAT TCT GTC TTG TGG-3′, antisense 5′-GGT CTG GGC CAT AGA ACT GA-3′, probe 5′-TGG TGG CC-3′. Quantitative PCR was performed on a Light Cycler (Roche Diagnostics Corporation). Data were analyzed employing the “Fit Points” and “Standard Curve Method” using hypoxanthine-guanine phosphoribosyltransferase (Hprt) as housekeeping gene to calculate the level of gene expression in relation to Hprt.

**Statistical Analysis**

Quantifiable data are expressed as mean and SE. After analyzing for Gaussian distribution the Mann–Whitney test was applied, defining different error probabilities (*p ≤ 0.05, **p ≤ 0.01).

**ETHICS STATEMENT**

All experiments performed were in accordance with German Animal Protection Law and were approved by the Animal Research Ethics Board of the Ministry of the Environment, Kiel, Germany.

**AUTHOR CONTRIBUTIONS**

KH performed the experiments, analysed the data and wrote the manuscript. MP wrote the manuscript. SB performed experiments and analysed data. AH performed experiments and analysed data. FD performed experiments. H-WM provided material. SR-J provided material. CH conceived and designed the experiments and wrote the manuscript.

**ACKNOWLEDGMENTS**

This work was supported by the Priority Program “Autoimmunity” of the University of Lübeck. We are thankful to Werner Müller for providing gp130-deficient breeding pairs. We are also grateful to Kerstin Traxel and Gabriele Röver for supplying and cleaning the lab and to Sarah Vieten and Gerhard Schultheiß for organizing the animal facility and taking care of the mice. The work of SR-J was supported by grants from the Deutsche Forschungsgemeinschaft (SFB841, project C1; SFB877, project A1) and by the Cluster of Excellence “Inflammation at Interfaces.”

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00836/full#supplementary-material.

**REFERENCES**

1. Fletcher JM, Lalor SJ, Sweeney CM, Tubriddy N, Mills KHG. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. *Clin Exp Immunol* (2010) 162:1–11. doi:10.1111/j.1365-2249.2010.04143.x

2. Petermann F, Korn T. Cytokines and effector T cell subsets causing autoimmune CNS disease. *FEBS Lett* (2011) 585:3747–57. doi:10.1016/j.febslet.2011.03.064

3. Fouser LA, Wright JF, D'Amore PP, Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity. *Immunol Rev* (2008) 226:87–102. doi:10.1111/j.1600-065X.2008.00712.x
12. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal regulation of pathogenic Th17 and regulatory T cells. Nat Immunol (2009) 10:703–8. doi:10.1038/nature06875

13. Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Annu Rev Immunol (2008) 26:737–67. doi:10.1146/annurev.immunol.26.092207.093535

14. Quirino GF, Nascimento MS, Davoli-Ferreira M, Sacramento LA, Lima MH, Almeida RP, et al. Interleukin-27 (IL-27) mediates susceptibility to visceral leishmaniasis by suppressing the IL-17-neutrophil response. Infect Immun (2016) 84:2289–98. doi:10.1128/IAI.00283-16

15. Zhou L, Lopes JE, Chong MMW, Ivanov II, Min R, victora GD, et al. TGFBeta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgamma function. Nature (2008) 453:236–40. doi:10.1038/nature06878

16. Bettini M, Vignali DAA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol (2009) 21:612–8. doi:10.1016/j.coi.2009.09.011

17. Stumhofer JS, Silver J, Hunter CA. Negative regulation of Th17 responses. Annu Rev Immunol (2007) 25:821–52. doi:10.1146/annurev.immunol.25.022106.141557

18. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgamma function. Nature (2008) 453:236–40. doi:10.1038/nature06878

19. Fitzgerald DC, Ciric B, Toulil T, Harle H, Grammatikopolou J, Das Sarma J, et al. Suppressive effects of IL-27 on Th17 cells and the effect of interferon-gamma on the polarization of Th17 cells. J Immunol (2007) 178:3268–75. doi:10.4049/jimmunol.178.5.3268

20. Neufert C, Becker C, Wirtz S, Fantini MC, Weigmann B, Galle PR, et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. Eur J Immunol (2007) 37:1809–16. doi:10.1002/eji.2005368896

21. Diven C, McGregor MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shamkii B, et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol (2009) 182:5748–56. doi:10.4049/jimmunol.0801162

22. Chong WP, Horai R, Mattapallil MJ, Silver PB, Chen J, Zhou R, et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun (2014) 50:12–22. doi:10.1016/j.jaut.2013.08.003

23. Do J, Kim D, Kim S, Valentin-Torres A, Dvorina N, Jang E, et al. Treg specific IL-27Ralpha deletion uncovers a key role for IL-27 in Treg function to control autoimmunity. Proc Natl Acad Sci U S A (2017) 114:10190–5. doi:10.1073/pnas.1700701114

24. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin-17 limits autoimmune encephalomyelitis by suppressing the development of interleukin-17-producing T cells. Nat Immunol (2006) 7:929–36. doi:10.1038/ni1375

25. Stumhofer JS, Laurence A, Wilson EH, Huang E, Tato CM, Johnson LM, et al. Interleukin-27 negatively regulates the development of interleukin-17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7:937–45. doi:10.1038/ni1376

26. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol (1989) 143:3517–23.

27. Hölscher C, Hölscher A, Rückerl D, Yoshimoto T, Yoshida H, Mak T, et al. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J Immunol (2005) 174:3534–44. doi:10.4049/jimmunol.174.6.3534

28. Rückerl D, Hessmann M, Yoshimoto T, Ehlers S, Hölscher C. Alternatively activated macrophages express the IL-27 receptor alpha chain WSX-1. Immunobiology (2006) 211:427–36. doi:10.1016/j.imbio.2006.05.008

29. Wirtz S, Tollef B, Galie PR, Schild HJ, Birkenbach M, Blumberg RS, et al. Protection from lethal septic peritonitis by neutralizing the biological function of interleukin-27. J Exp Med (2006) 203:1875–81. doi:10.1084/jem.20060471

30. Sander LE, Obermeier F, Dierssen U, Dierssen M, Seidler U, et al. Gastric IL-17 signaling promotes development of acute experimental colitis by facilitating early neutrophil/macrophage recruitment and activation. J Immunol (2008) 181:3586–94. doi:10.4049/jimmunol.181.5.3586

31. Sodenkamp J, Behrends J, Förster I, Müller W, Ehlers S, Hölscher C, gp130 on macrophages/granulocytes modulates inflammation during experimental tuberculosis. Eur J Cell Biol (2011) 90:505–14. doi:10.1016/j.ejcb.2010.10.010

32. Lutz HH, Sackdor SD, Kroy DC, Gassler N, Trautwein C. Deletion of gp130 in myeloid cells modulates IL-6-release and is associated with more severe liver injury of Con A hepatitis. Eur J Cell Biol (2012) 91:576–81. doi:10.1016/j.ejcb.2011.09.006

33. Watzlawick R, Kengg EE, Liu FD, Schwab JM, Hamann A. Anti-inflammatory effects of IL-27 in zymosan-induced peritonitis: inhibition of neutrophil recruitment partially explained by impaired mobilization from bone marrow and reduced chemokine levels. PLoS One (2015) 10:137561. doi:10.1371/journal.pone.0137561

34. Quirino GF, Nascimento MS, Davoli-Ferreira M, Sacramento LA, Lima MH, Almeida RP, et al. Interleukin-27 (IL-27) mediates susceptibility to visceral leishmaniasis by suppressing the IL-17-neutrophil response. Infect Immun (2016) 84:2289–98. doi:10.1128/IAI.00283-16

35. Zhou L, Lopes JE, Chong MMW, Ivanov II, Min R, Victora GD, et al. TGFBeta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgamma function. Nature (2008) 453:236–40. doi:10.1038/nature06878

36. Bettini M, Vignali DAA. Regulatory T cells and inhibitory cytokines in autoimmunity. Curr Opin Immunol (2009) 21:612–8. doi:10.1016/j.coi.2009.09.011

37. Stumhofer JS, Silver J, Hunter CA. Negative regulation of Th17 responses. Semin Immunol (2007) 19:394–9. doi:10.1016/j.smim.2007.11.006

38. Pfanz S, Hibbert L, Mattson J, Rosales R, Vaiberg B, Baazn JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol (2004) 172:2225–31. doi:10.4049/jimmunol.172.4.2225

39. Chong WP, Horai R, Mattapallil MJ, Silver PB, Chen J, Zhou R, et al. IL-27p28 inhibits central nervous system autoimmunity by concurrently antagonizing Th1 and Th17 responses. J Autoimmun (2014) 50:12–22. doi:10.1016/j.jaut.2013.08.003

40. Do J, Kim D, Kim S, Valentin-Torres A, Dvorina N, Jang E, et al. Treg specific IL-27Ralpha deletion uncovers a key role for IL-27 in Treg function to control autoimmunity. Proc Natl Acad Sci U S A (2017) 114:10190–5. doi:10.1073/pnas.1700701114

41. Batten M, Li J, Yi S, Kljavin NM, Danilenko DM, Lucas S, et al. Interleukin-27 limits autoimmune encephalomyelitis by suppressing the development of interleukin-17-producing T cells. Nat Immunol (2006) 7:929–36. doi:10.1038/ni1375

42. Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol (1989) 143:3517–23.
44. Liu J-Q, Liu Z, Zhang X, Shi Y, Talebian F, Carl JW Jr, et al. Increased Th17 and regulatory T cell responses in EBV-induced gene 3-deficient mice lead to marginally enhanced development of autoimmune encephalomyelitis. *J Immunol* (2012) 188:7:3099–106. doi:10.4049/jimmunol.1100106

45. Kimura A, Naka T, Kishimoto T. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. *Proc Natl Acad Sci U S A* (2007) 104:12099–104. doi:10.1073/pnas.0702568104

46. Nishihara M, Ogura H, Ueda N, Tsuruoka M, Kitabayashi C, Tsuji F, et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimal effect on that of Treg in the steady state. *Int Immunol* (2007) 19:695–702. doi:10.1093/intimm/dxm045

47. Serada S, Fujimoto M, Mihara M, Koike N, Ohsugi Y, Nomura S, et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci U S A* (2008) 105:9041–6. doi:10.1073/pnas.0802218105

48. Korn T. Pathophysiology of multiple sclerosis. *J Neurol* (2008) 255(6):2–6. doi:10.1007/s00415-008-6001-2

49. El-Behi M, Ceric B, Yu S, Zhang G-X, Fitzgerald DC, Rostami A. Differential effect of IL-27 on developing versus committed Th17 cells. *J Immunol* (2009) 183:4957–67. doi:10.4049/jimmunol.0900735

50. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Lauber T, et al. Dendritic cells permit immune invasion of the brain in an animal model of multiple sclerosis. *Cell* (2005) 117:328–34. doi:10.1016/j.cell.2005.09.012

51. Comabella M, Montalban X, Munz C, Lunemann JD. Targeting dendritic cells to treat multiple sclerosis. *Nat Rev Neurol* (2010) 6:499–507. doi:10.1038/nnrnneurol.2010.112

52. Yoge N, Frommer F, Lukas D, Kautz-Neu K, Karram K, Ielo D, et al. Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor (+) regulatory T cells. *Immunity* (2012) 37:264–75. doi:10.1016/j.immuni.2012.05.025

53. Mascarfoni ID, Yeste A, Vieta SM, Nadjo D, Sloma I, et al. IL-6 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. *Nat Immunol* (2013) 14:1054–63. doi:10.1038/nature13695

54. Fielding CA, Mcloughlin RM, Mcleod L, Colmont CS, Najdovska M, Grail D, et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. *J Immunol* (2008) 181:2188–95. doi:10.4049/jimmunol.181.3.2189

55. Croxford AL, Karbach S, Kurschus FC, Wortge S, Nikolaev A, Yohev N, et al. IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions. *J Immunol* (2001) 167:695–702. doi:10.1084/jem.193.6.713

56. Huitinga I, Van Rooijen N, De Groot CJ, Uitdehaag BM, Dijkstra CD. Myeloid-derived suppressor cells are increased in the CNS during EAE in gp130-Deficient Mice. *J Immunol* (2012) 188:6521–31. doi:10.4049/jimmunol.1200135

57. Clausen BE, Burkhardt C, Reith W, Renkawitz R, Förster I. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. *Am J Pathol* (2014) 183:4957–67. doi:10.4049/jimmunol.0900735

58. Huitinga I, Van Rooijen N, De Groot CJ, Uitdehaag BM, Dijkstra CD. Myeloid-derived suppressor cells are increased in the CNS during EAE in gp130-Deficient Mice. *J Immunol* (2012) 188:6521–31. doi:10.4049/jimmunol.1200135

59. Martorell L, et al. Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis. *Exp Neurol* (2016) 286:50–60. doi:10.1016/j.expneurol.2016.09.012

60. Haroon E, Drögelmüller K, Händel U, Brunn A, Reinhold D, Nishanth G, et al. Gp130-dependent astrogliosis is critical for the control of auto- immune central nervous system inflammation. *J Immunol* (2011) 186:6521–31. doi:10.4049/jimmunol.1102274

61. Händel U, Brunn A, Drögelmüller K, Müller W, Deckert M, Schütter D. Neuronal gp130 expression is crucial to prevent neuronal loss, hyperinflammation, and lethal course of murine Toxoplasma encephalitis. *Am J Pathol* (2012) 181:163–73. doi:10.1016/j.ajpath.2012.03.029

62. Villarino AV, Larkin J III, Saris CJM, Caton AJ, Lucas S, Wong T, et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. *J Immunol* (2005) 174:7684–91. doi:10.4049/jimmunol.174.12.7684

63. Kishimoto T, Tanaka T, Yoshida K, Akira S, Ito H, Ofuji T, et al. Interleukin-35-producing B cells are critical regulators of immunity during Toxoplasma infection and improves systemic insulin action. *J Autoimmun* (2010) 6:499–507. doi:10.1038/nnrnneurol.2010.112

64. Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, Holscher C, et al. An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-17 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. *J Biol Chem* (2013) 288:4346–54. doi:10.1074/jbc.M112.432955

65. Shoenfeld Y, Knecht A, Lichtenstein P, O'Connell RA, Stiborova U, Rosenberg E, et al. Interleukin-17-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. *J Autoimmun* (2014) 50:366–70. doi:10.1016/j.jaut.2012.11.003

66. Gao W, Thompson L, Zhou Q, Puteth P, Fahmy TM, Strom TB, et al. Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6. *Cell Cycle* (2008) 7:1444–50. doi:10.1089/cc.2007.09.8.343

67. Wang X, Lupardus P, Laporte SL, Garcia KC. Structural biology of shared cytokine receptors. *Annu Rev Immunol* (2009) 27:29–60. doi:10.1146/annurev.immunol.050808.105535

68. Reik C, Luebke J, Huhn C, Brunn A, De Santis G, Hildeman EA, et al. Interleukin-13 suppresses experimental autoimmune encephalomyelitis. *Am J Pathol* (2011) 179:573–84. doi:10.1016/j.ajpath.2011.06.011

69. Holz et al. EAE in gp130-Deficient Mice
83. Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci (2013) 16:1618–26. doi:10.1038/nn.3531

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.